TELA Bio Q2 2023 revenue $14.5M (+39% YoY); reaffirms FY23 guidance $60-65M

TELA Bio, Inc.

2023-Q2 EPS reported -$1.08 revenue$26,403,000

Q2 revenue $14.5M, up 39% YoY; H1 revenue $26.4M, up 42% YoY.
Gross margin improved to 70% vs 63% in Q2 2022 due to better inventory management.
Net loss $10.8M, narrower than $12.7M loss in prior-year quarter.
FY2023 revenue guidance reaffirmed: $60-65M, representing 45-57% growth.
Cash $65.3M after underwritten public offering netting ~$46.4M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.